Supriya Lifescience share news, announcements and annual reports
NSE: SUPRIYABSE: 543434Pharmaceuticals & BiotechnologySmall Cap
Supriya Lifescience Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2021 · Issue price ₹274
Last close ₹869.30up ₹7.05 (0.82%)BSE ₹868.40
Share price at the NSE close on 29 Oct 2026. Previous close ₹862.25.
29 Oct: open ₹869.25, high ₹873.55, low ₹858.05
52-week range of traded prices to 29 Oct 2026
₹545.50Low, 24 Mar 2026₹1,085.00High, 1 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6,996 Cr733rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 35.27
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.84
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.12%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 87,17549.0% delivered
Supriya Lifescience has 383 announcements on record, routine notices left out; 3 in the 30 days to 30 Oct 2026, the latest on 19 Oct 2026.
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Supriya Lifescience quarterly results
Aug13Thu
The board met on 13 Aug 2026 to consider financial results
Notice filed 6 Aug 2026
To consider and approve the financial results for the period ended Jun 30, 2026
Supriya Lifescience annual reports, presentations and earnings calls
The company's own documents, latest first.Supriya Lifescience financials, year by year
Annual reports5
- Annual report, year to Mar 20261 Sep 2026
- Annual report, year to Mar 20251 Sep 2025
- Annual report, year to Mar 20245 Sep 2024
- Annual report, year to Mar 20236 Sep 2023, a zip file
- Annual report, year to Mar 202223 Aug 2022, a zip file
Investor presentations22
- Investor Presentation13 Aug 2026
- Investor Presentation27 May 2026
- Investor Presentation9 Feb 2026
- This is to inform you that an earnings call will be held on Tuesday, February 10, 2026, at 11.00 A.M. IST to discuss operational and financial performance of the Company for the quarter and nine months ended December 31, 2025. The invite giving requisite details including the pre-registration link and dial-in details is enclosed herewith. The investor presentation shall be shared with the Exchanges separately.Kindly take the information on record.4 Feb 2026
- Investor Presentation12 Nov 2025
17 earlier presentations
- This is to inform you that an earnings call will be held on Thursday, November 13, 2025 at 11.00 A.M. IST to discuss operational and financial performance of the Company for the quarter and half year ended September 30, 2025. The invite giving requisite details including the pre-registration link and dial-in details is enclosed herewith. The investor presentation shall be shared with the Exchanges separately.Kindly take the information on record.9 Nov 2025
- Investor Presentation13 Aug 2025
- Investor Presentation27 May 2025
- Investor Presentation24 Jan 2025
- Investor Presentation28 Oct 2024
- Investor Presentation10 Aug 2024
- Investor Presentation28 May 2024
- Investor Presentation7 Feb 2024
- Investor Presentation7 Nov 2023
- Investor Presentation3 Aug 2023
- Investor Presentation27 May 2023
- Investor Presentation14 Feb 2023
- We are enclosing the Investor Presentation.You are requested to kindly take the same on record.11 Nov 2022
- Investor PresentationPursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Investor Presentation. You are requested to kindly take the same on record.13 Aug 2022
- Investor PresentationThis has a reference to our intimation letter dated May 21, 2022, wherein the Company has submitted Investor Presentation, inter-alia, to the Stock Exchanges.In connection herewith, please find enclosed herewith revised Investor presentation.You are requested to kindly take the same on record.21 May 2022
- Investor PresentationPursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Investor Presentation.You are requested to kindly take the same on record.21 May 2022
- Investor Presentation21 Jan 2022
Earnings calls33
- Transcript18 Aug 2026
- Link of Recording14 Aug 2026
- Transcript2 Jun 2026
- Link of Recording28 May 2026
- Transcript17 Feb 2026
28 earlier call documents
- Link of Recording10 Feb 2026
- Transcript18 Nov 2025
- Link of Recording of the Earnings Call for the quarter and half year ended September 30, 2025 is enclosed herewith.13 Nov 2025
- Transcript19 Aug 2025
- Link of Recording14 Aug 2025
- Transcript31 May 2025
- Link of Recording28 May 2025
- Transcript31 Jan 2025
- Link of Recording27 Jan 2025
- Transcript4 Nov 2024
- Link of Recording28 Oct 2024
- Transcript19 Aug 2024
- Link of Recording12 Aug 2024
- Transcript5 Jun 2024
- Link of Recording29 May 2024
- Transcript13 Feb 2024
- Link of Recording8 Feb 2024
- Transcript13 Nov 2023
- Link of Recording8 Nov 2023
- Link of Recording4 Aug 2023
- Transcript2 Jun 2023
- Link of Recording29 May 2023
- Transcript20 Feb 2023
- Link of Recording15 Feb 2023
- Transcript of Analysts/Institutional Investor Meet/Con. Call17 Nov 2022
- Transcript of Analysts/Institutional Investor Meet/Con. Call Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby enclose the transcript of the Earnings call held on Tuesday, August 16, 2022 at 3.00 P.M. IST to discuss operational and financial performance of the Company for the quarter ended June 30, 2022 (Q1 of FY 2022-23).This is for your information and records.23 Aug 2022
- Transcript of Analysts/Institutional Investor Meet/Con. Call Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby enclose the transcript of the Earnings call held on Monday, May 23, 2022 at 3.30 P.M. IST to discuss operational and financial performance of the Company for the fourth quarter and year ended March 31, 2022.This is for your information and records.27 May 2022
- Transcript of the Earnings Call for Q3 of FY 2021-22 for the quarter and nine months ended December 31, 202125 Jan 2022
Supriya Lifescience share news and announcements
Newest first. Page 1 of 8.
Oct 2026
19 Oct
13 Oct · General Updates
8 Oct
Sep 2026
23 Sep
20 Sep · Analysts
11 Sep · Analysts
2 Sep
2 Sep
2 Sep · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.
Aug 2026
26 Aug · Corporate action
10 Aug · Analysts
6 Aug · Board meeting
Jul 2026
21 Jul · Meeting
4 Jul
Jun 2026
23 Jun
15 Jun · Analysts
9 Jun · Analysts
May 2026
27 May · Results
23 May · Analysts
Apr 2026
Mar 2026
24 Mar · Management
10 Mar · Meeting
10 Mar · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted. The response of the Company is awaited.
Feb 2026
9 Feb · Results
9 Feb · Board meeting
2 Feb · Board meeting
Jan 2026
13 Jan · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Dec 2025
30 Dec · Rating
Nov 2025
26 Nov · Analysts
Oct 2025
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 14 Aug 2026Resultsdown 2.69%−2.4 pts vs Nifty 500market median −0.7% · five sessions −0.2% (+0.4 pts vs Nifty 500) · volume 6.6× usual · delivery −15.3 pts against usual · The announcement
- 29 May 2026Resultsup 20.00%+21.4 pts vs Nifty 500market median −0.7% · five sessions +17.9% (+20.0 pts vs Nifty 500) · volume 24.9× usual · delivery −23.7 pts against usual · The announcement
- 10 Feb 2026Resultsdown 0.14%−0.4 pts vs Nifty 500market median −0.7% · five sessions −2.1% (−1.2 pts vs Nifty 500) · volume 2.3× usual · delivery −2.6 pts against usual · The announcement
- 31 Dec 2025Credit ratingup 2.54%+1.7 pts vs Nifty 500market median 0.0% · five sessions +2.4% (+1.0 pts vs Nifty 500) · volume 1.1× usual · delivery +8.7 pts against usual · The announcement
- 13 Nov 2025Resultsup 3.19%+3.3 pts vs Nifty 500market median −0.7% · five sessions +0.5% (+0.2 pts vs Nifty 500) · volume 4.1× usual · delivery −18.8 pts against usual · The announcement
- 14 Aug 2025Resultsdown 0.88%−0.8 pts vs Nifty 500market median −0.7% · five sessions +6.0% (+4.0 pts vs Nifty 500) · volume 4.4× usual · delivery +8.0 pts against usual · The announcement
- 28 May 2025Dividenddown 0.95%−0.8 pts vs Nifty 500market median 0.0% · five sessions −2.0% (−1.6 pts vs Nifty 500) · volume 2.3× usual · delivery −13.4 pts against usual · The announcement
- 1 Feb 2025Board or managers changedup 0.15%+0.1 pts vs Nifty 500market median 0.0% · five sessions +4.6% (+4.1 pts vs Nifty 500) · volume 0.4× usual · delivery −8.1 pts against usual · The announcement
- 27 Jan 2025Resultsdown 5.35%−3.4 pts vs Nifty 500market median −0.7% · five sessions +2.8% (+1.6 pts vs Nifty 500) · volume 1.9× usual · delivery −4.9 pts against usual · The announcement
- 27 Jan 2025Board or managers changeddown 5.35%−3.4 pts vs Nifty 500market median 0.0% · five sessions +2.8% (+1.6 pts vs Nifty 500) · volume 1.9× usual · delivery −4.9 pts against usual · The announcement
11 earlier announcements
- 12 Aug 2024Resultsup 13.89%+13.9 pts vs Nifty 500market median −0.7% · five sessions +18.7% (+17.8 pts vs Nifty 500) · volume 16.9× usual · delivery −28.9 pts against usual · The announcement
- 29 May 2024Dividenddown 4.23%−3.6 pts vs Nifty 500market median 0.0% · five sessions −7.2% (−2.2 pts vs Nifty 500) · volume 3.3× usual · delivery −8.2 pts against usual · The announcement
- 29 May 2024Board or managers changeddown 4.23%−3.6 pts vs Nifty 500market median 0.0% · five sessions −7.2% (−2.2 pts vs Nifty 500) · volume 3.3× usual · delivery −8.2 pts against usual · The announcement
- 7 Aug 2023Resultsdown 2.23%−2.6 pts vs Nifty 500market median −0.7% · five sessions −4.6% (−4.4 pts vs Nifty 500) · volume 0.6× usual · delivery −0.1 pts against usual
- 29 May 2023Dividenddown 1.85%−2.3 pts vs Nifty 500market median 0.0% · five sessions −2.0% (−2.8 pts vs Nifty 500) · volume 0.5× usual · delivery +3.8 pts against usual · The announcement
- 29 May 2023Board or managers changeddown 1.85%−2.3 pts vs Nifty 500market median 0.0% · five sessions −2.0% (−2.8 pts vs Nifty 500) · volume 0.5× usual · delivery +3.8 pts against usual · The announcement
- 26 May 2023Dividenddown 0.29%−1.2 pts vs Nifty 500market median 0.0% · five sessions −1.0% (−2.3 pts vs Nifty 500) · volume 1.1× usual · delivery −7.5 pts against usual · The announcement
- 24 Jan 2023Board or managers changeddown 1.86%−1.8 pts vs Nifty 500market median 0.0% · five sessions −3.3% (−0.3 pts vs Nifty 500) · volume 0.9× usual · delivery −7.6 pts against usual · The announcement
- 28 Sep 2022Board or managers changeddown 7.77%−7.0 pts vs Nifty 500market median 0.0% · five sessions −7.2% (−8.9 pts vs Nifty 500) · volume 5.8× usual · delivery −2.2 pts against usual · The announcement
- 23 May 2022Dividenddown 3.33%−2.9 pts vs Nifty 500market median 0.0% · five sessions −7.3% (−7.1 pts vs Nifty 500) · volume 1.1× usual · delivery +1.9 pts against usual · The announcement
- 21 Jan 2022Resultsdown 18.14%−17.0 pts vs Nifty 500market median −0.7% · five sessions −18.7% (−14.6 pts vs Nifty 500) · delivery −0.4 pts against usual · The announcement
Supriya Lifescience results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.